These findings describe not only the loss of ERα correlated with miR-192-5p, induced by LY6K, in ERα-positive breast cancer but also how upregulation of miR-500a-3p affects tamoxifen-induced cell death in ERα-negative breast cancer. Here, LY6K is linked to breast carcinoma.